OncoMatch/Clinical Trials/NCT07144020
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
Is NCT07144020 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CD117 CAR T-cells for acute myeloid leukemia.
Treatment: CD117 CAR T-cells — A Clinical Study on the Safety and Effectiveness of Donor Derived CD117 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: KIT overexpression (CD117-positive)
CD117-positive Acute Myeloid Leukemia (AML)
Disease stage
Required: Stage RELAPSED, REFRACTORY (2016 WHO classification; Chinese Guidelines for the Diagnosis and Management of Relapsed/Refractory Acute Myeloid Leukemia (2017 Edition))
Diagnosis must meet the 2016 WHO classification criteria for AML and fulfill the definitions for relapsed or refractory disease per the Chinese Guidelines for the Diagnosis and Management of Relapsed/Refractory Acute Myeloid Leukemia (2017 Edition), with no available suitable standard therapeutic options or registered clinical trials.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
serum creatinine ≤1.5 × uln (≤176.8 μmol/l)
Liver function
total bilirubin ≤1.5 × uln (≤51 μmol/l) alt and ast ≤3 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥50% as assessed by echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify